Thursday, April 30, 2020 | 8:30 am - 12:00 pm
Friday, May 1, 2020 | 8:30 am - 12:15 pm
VIRTUAL SYMPOSIUM
Overview | Agenda | Registration | Contact
Overview
This online symposium will focus on two major aspects: (1) novel clinical trial design and advanced quantitative models during the development of cancer immunotherapy, and (2) computational algorithms and data integration techniques that are under active development to solve the challenges raised in cutting edge high throughput sequencing being applied to cancer immunology and immuno-oncology research and clinical applications.
Agenda
DAY 1: THURSDAY, APRIL 30, 2020 |
|
8:25 am |
Introductions Li Zhang, PhD |
8:30 am |
Welcome Eric Small, MD, FASCO |
Overview of Cancer Immunology and Immunotherapy |
|
8:45 am |
KEYNOTE: Mechanisms of Response and Resistance to Cancer Immunotherapy Lawrence Fong, MD |
Session 1: Clinical Study Design and Novel Quantitative Methodology (Chair: Ron Yu, PhD, Gilead) |
|
9:35 am |
KEYNOTE: Novel Bayesian Adaptive Trial Designs to Accelerate Development of Immunotherapy Ying Yuan, PhD, FRSC |
10:20 am |
A practical design approach to Phase III trials in immuno-oncology Keaven Anderson, PhD |
10:50 am |
Design, monitoring and analysis of randomized clinical trials based on the restricted mean survival time Bo Huang, PhD |
11:20 am |
Q&A with Session 1 speakers Ying Yuan, PhD, FRSC |
11:30 am |
Sponsor Presentation: Immune Repertoire Sequencing for Immuno-Oncology Biomarker Discovery Timothy Looney, PhD |
12:00 pm |
Adjourn Day 1 |
DAY 2: FRIDAY, MAY 1, 2020 |
|
Session 2: Cutting-edge Technologies and Advancements in Computational Approaches (Chair: Li Zhang, PhD, UCSF) |
|
8:30 am |
KEYNOTE: Biomarkers and regulators of tumor immunotherapy response Shirley Liu, PhD |
9:15 am |
Understanding immune responses to cancer from single-cell data Matthew H. Spitzer, PhD |
9:45 am |
Leveraging Multi-Omics Data To Better Understand Cancer Marina Sirota, PhD |
10:15 am |
Q&A with Session 2 speakers Shirley Liu, PhD |
Session 3: Enhanced Personalized Immunotherapy (Chair: Ray Lin, PhD, Genentech) |
|
10:30 am |
Estimating and Interpreting Treatment Effect in Oncology Immune Therapies Susan Halabi, PhD |
11:00 am |
Dose Selection for Cancer Immunotherapy Yaning Wang, PhD |
11:30 am |
Multiplexed Single Cell Genomics Jimmie Ye, PhD |
12:00 pm |
Q&A with Session 3 speakers Susan Halabi, PhD |
12:10 pm |
Closing remarks Li Zhang, PhD |
12:15 pm |
Adjourn Day 2 |
Registration
**Registration is now closed**
Registrants: please check your email for login/participation details. If you did not receive the Zoom link and instructions, contact Erin Hayes ([email protected]) directly for assistance.
Contact
For general event questions, please contact:
Geraldine Pacheco, [email protected]
For questions related to session topics and sponsorship, please contact:
Li Zhang, PhD, [email protected]
Planning Committee
- Li Zhang, PhD (Chair), Associate Professor, Department of Medicine and Department of Epidemiology and Biostatistics, UCSF
- Jing Huang, PhD, SVP of Bioinformatics & Data Science, Veracyte, Inc.
- Ray Lin, PhD, Principal Statistical Scientist, Department of Biostatistics, Genentech/Roche
- Timothy Looney, PhD, Associate Director, Bioinformatics at Thermo Fisher Scientific
- Ron Yu, PhD, Senior Director, Biostatistics at Gilead Sciences
- Tao He, PhD, Assistant Professor of Statistics, Department of Mathematics, San Francisco State University
Scientific Advisors
- Mi-OK Kim, PhD, Director, Biostatistics Core, UCSF Helen Diller Family Comprehensive Cancer Center; Professor in Residence, Dept. of Epidemiology & Biostatistics, UCSF
- Lawrence Fong, MD, PhD, Efim Guzik Distinguished Professor in Cancer Biology; Leader, Cancer Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center
Event Sponsors
**This retreat is supported by the Biostatistics Shared Resource and the Cancer Immunology Program of the UCSF Helen Diller Family Comprehensive Cancer Center; Thermo Fisher Scientific; San Francisco Bay Area Chapter of the American Statistical Association; and DahShu**